Academic Appointments


Professional Education


  • Doctor of Philosophy, Yonsei University (2018)
  • Bachelor of Science, Yonsei University (2011)

All Publications


  • Senescent-like activated naive B cells contribute to progression to clinical rheumatoid arthritis. Nature aging Wu, X., Zhang, M., Moon, J. S., Song, E. K., Abrams, J. C., van Dam, L. S., Sharpe, O., Wang, Z., Feser, M. L., Moss, L., Ho, P. P., Smith, M. H., Donlin, L. T., Buckner, J. H., James, E. A., Firestein, G. S., Okamoto, Y., Lanz, T. V., Meffre, E., Lyu, A., Holers, V. M., Deane, K. D., Robinson, W. H. 2026; 6 (10): 2143-2163

    Abstract

    Rheumatoid arthritis (RA) is an autoimmune disease marked by joint and systemic inflammation. Anticitrullinated protein antibodies identify an at-risk stage that precedes clinical RA, yet the mechanisms driving disease progression remain poorly understood. Here we show that anticitrullinated-protein-antibody-positive individuals who progressed to RA exhibited a marked expansion of CXCR5+CD69+-activated naive B cells (aNAVs) before disease onset. These cells displayed inflammatory and senescent-like transcriptional programs and expressed polyreactive, autoreactive IgM B cell receptors. The expansion, activation and senescent-like phenotype of aNAVs were validated in multiple independent preclinical RA cohorts, and aNAVs were detectable in RA synovium. In vitro, aNAVs stimulated with citrullinated antigens promoted T cell activation in a human-leukocyte-antigen-dependent manner. Chronic exposure to citrullinated antigens and CpG (an innate immune stimulant) synergistically drove activation and senescent-like programming in naive B cells from individuals with RA. These findings identify senescent-like aNAVs as potential contributors and therapeutic targets for RA prevention.

    View details for DOI 10.1038/s43587-026-01236-6

    View details for PubMedID 42875583

    View details for PubMedCentralID 11997871

  • Cross-presentation of citrullinated antigens drives cytotoxic CD8+ T cell responses in rheumatoid arthritis. bioRxiv : the preprint server for biology Moon, J. S., Zhang, M., van Dam, L. S., Song, E. K., Sharpe, O., Carman, J. A., Ramirez, D. C., Smith, M. H., Donlin, L. T., Howard, M. C., Davis, M. M., Robinson, W. H. 2026

    Abstract

    Rheumatoid arthritis (RA) is an autoimmune synovitis marked by anti-citrullinated protein antibodies (ACPAs) and infiltration of the synovium by activated immune cells. In ACPA-positive RA, CD8+ T cells are elevated in both the blood and synovium, and can be activated by MHC class I-restricted citrullinated autoantigens to mediate cytotoxic effector function. However, the mechanisms underlying the activation of cytotoxic CD8+ T cells in RA remain poorly understood. Here, single-cell transcriptomic and T cell receptor repertoire analysis of RA blood and synovial T cells revealed shared clonally expanded cytotoxic CD8+ T cell programs, with synovial enrichment of activated effector and proliferating populations and increased frequencies of GZMB + IFNG + CD8+ T cells. We demonstrated that RA-associated oral bacteria stimulate neutrophil extracellular trap (NET) formation, leading to the peptidyl arginine deiminases (PAD)-dependent generation of extracellular citrullinated bacterial and host proteins. We further demonstrated that these antigens can be cross-presented to CD8+ T cells via HLA class I molecules expressed by monocyte-derived dendritic cells (MoDCs) and autoreactive ACPA-expressing B cells. Toll-like receptor (TLR) signaling, particularly TLR4 activation by citrullinated antigens, enhanced cross-presentation of citrullinated antigens and promoted CD8+ T cell activation and clonal expansion. In turn, citrullinated antigens stimulated autoreactive B cells to produce IL-8, which recruited CXCR1/2+ cytotoxic CD8+ T cells and amplified B cell-CD8+ T cell interactions. These findings reveal a mechanistic pathway linking microbial triggers, antigen presentation, and cytotoxic CD8+ T cell responses that may drive joint destruction in RA.

    View details for DOI 10.64898/2026.06.03.729882

    View details for PubMedID 42327047

    View details for PubMedCentralID PMC13278032

  • Cytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy. Proceedings of the National Academy of Sciences of the United States of America Moon, J. S., Moutusy, S. I., Zhang, M., Ndayisaba, A., Rodriguez, D., El Kodsi, D. N., Kuzkina, A., Younis, S., Jahanbani, S., Dam, L. S., Courtney, Y., Netanel, A., Sharpe, O., Miglis, M. G., Steinman, L., Khurana, V., Jahanbani, F., Robinson, W. H. 2026; 123 (14): e2537271123

    Abstract

    Multiple system atrophy (MSA) is a progressive neurologic disease, known as an α-synucleinopathy. There are currently no effective disease-modifying therapies for MSA. While neuroinflammation is a hallmark of MSA, the contribution of adaptive immune mechanisms remains poorly understood. Here, we profiled peripheral and central T cell responses in patients with MSA, in comparison with Parkinson's disease (PD) and healthy control cohorts, using single-cell transcriptomics, flow cytometry, and antigen-specific functional assays. We demonstrated that peripheral T cells from MSA patients are activated and skewed toward cytotoxic and inflammatory phenotypes. Single-cell transcriptomics further revealed clonal expansion of cytotoxic CD8+ T cells expressing GZMB, GNLY, and chemokine and integrin programs associated with brain homing. We also demonstrated that both CD4+ and CD8+ T cells from MSA patients recognize α-synuclein monomers and preformed fibrils in an HLA class I/II-dependent manner, driving proliferation, clonal expansion, and acquisition of cytotoxic features. Consistent with these peripheral responses, CD8+ T cell density was increased in the parietal cortex of postmortem MSA brain tissues, along with cytotoxic (GZMB+, GZMK+) and proinflammatory (IFNγ+) CD8+ T cells. Together, these findings demonstrate that cytotoxic T cells targeting α-synuclein are engaged in MSA, suggesting that their activity may contribute to neuroinflammation and disease progression, and highlighting this immune axis as a candidate therapeutic target for further investigation.

    View details for DOI 10.1073/pnas.2537271123

    View details for PubMedID 41911451

  • Antigen-specific B cells cross-present citrullinated proteins to activate CD8 T cells in rheumatoid arthritis Moon, J., Van Dam, L., Smith, M., Donlin, L. T., Sharpe, O., Robinson, W. H. OXFORD UNIV PRESS. 2025
  • Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis van Dam, L., Younis, S., Moon, J., Zhang, M., Parfasar, S., Horomanski, A., Sharpe, O., van Leeuwen, J., Lanz, T., van Kooten, C., Teng, O., Robinson, W. WILEY. 2024: 3781-3785
  • Lrig1-expression confers suppressive function to CD4+ cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis. Nature communications Moon, J. S., Ho, C. C., Park, J. H., Park, K., Shin, B. Y., Lee, S. H., Sequeira, I., Mun, C. H., Shin, J. S., Kim, J. H., Kim, B. S., Noh, J. W., Lee, E. S., Son, J. Y., Kim, Y., Lee, Y., Cho, H., So, S., Park, J., Choi, E., Oh, J. W., Lee, S. W., Morio, T., Watt, F. M., Seong, R. H., Lee, S. K. 2023; 14 (1): 5382

    Abstract

    Regulatory T cells (Treg) are CD4+ T cells with immune-suppressive function, which is defined by Foxp3 expression. However, the molecular determinants defining the suppressive population of T cells have yet to be discovered. Here we report that the cell surface protein Lrig1 is enriched in suppressive T cells and controls their suppressive behaviors. Within CD4+ T cells, Treg cells express the highest levels of Lrig1, and the expression level is further increasing with activation. The Lrig1+ subpopulation from T helper (Th) 17 cells showed higher suppressive activity than the Lrig1- subpopulation. Lrig1-deficiency impairs the suppressive function of Treg cells, while Lrig1-deficient naïve T cells normally differentiate into other T cell subsets. Adoptive transfer of CD4+Lrig1+ T cells alleviates autoimmune symptoms in colitis and lupus nephritis mouse models. A monoclonal anti-Lrig1 antibody significantly improves the symptoms of experimental autoimmune encephalomyelitis. In conclusion, Lrig1 is an important regulator of suppressive T cell function and an exploitable target for treating autoimmune conditions.

    View details for DOI 10.1038/s41467-023-40986-4

    View details for PubMedID 37666819

    View details for PubMedCentralID 7882196

  • Anti-citrullinated protein antibodies with multiple specificities ameliorate collagen antibody-induced arthritis in a time-dependent manner. Arthritis & rheumatology (Hoboken, N.J.) Gomez, A. M., Brewer, R. C., Moon, J. S., Acharya, S., Kongpachith, S., Wang, Q., Jahanbani, S., Wong, H. H., Lanz, T. V., Love, Z. Z., Min-Oo, G., Niedziela-Majka, A., Robinson, W. H. 2023

    Abstract

    Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) and have long been regarded as pathogenic. Despite substantial in vitro evidence supporting this claim, reports investigating the pro-inflammatory effects of ACPAs in animal models of arthritis are rare and include mixed results. Here, we sequenced the plasmablast antibody repertoire of a RA patient and functionally characterized the encoded ACPAs.We expressed ACPAs from the antibody repertoire of a RA patient and characterized their autoantigen specificities on antigen arrays and ELISAs. Binding affinities were estimated by bio-layer interferometry. Select ACPAs (n=9) were tested in the collagen-antibody induced arthritis (CAIA) mouse model, to evaluate their effects on joint inflammation.Recombinant ACPAs bound preferentially, and with high affinity (nM range), to citrullinated (cit) autoantigens (primarily histones and fibrinogen), and to auto-citrullinated peptidylarginine deiminase 4 (PAD4). ACPAs were grouped for in vivo testing based on their predominant cit-antigen specificities. Unexpectedly, injections of recombinant ACPAs significantly reduced paw thickness and arthritis severity in CAIA mice, as compared to isotype-matched control antibodies (p≤0.001). Bone erosion, synovitis, and cartilage damage were also significantly reduced (p≤0.01). This amelioration of CAIA was observed for all the ACPAs tested and was independent of cit-PAD4 and cit-fibrinogen specificities. Further, disease amelioration was more prominent when ACPAs were injected at earlier stages of CAIA than at later phases of the model.Recombinant, patient-derived ACPAs ameliorated CAIA. Their anti-inflammatory effects were more preventative than therapeutic. This study highlights a potential protective role for ACPAs in arthritis.

    View details for DOI 10.1002/art.42679

    View details for PubMedID 37610274

  • Clonally Expanded Cytotoxic CD8<SUP>+</SUP> T cells Target Citrullinated Antigens In ACPA<SUP>+</SUP> Rheumatoid Arthritis Moon, J., Younis, S., Sharpe, O., Rao, N. L., Carman, J. A., James, E. A., Buckner, J. H., Deane, K. D., Holers, V., Donlin, L. T., Davis, M. M., Robinson, W. H. AMER ASSOC IMMUNOLOGISTS. 2023
  • Cytotoxic CD8+ T cells target citrullinated antigens in rheumatoid arthritis. Nature communications Moon, J. S., Younis, S., Ramadoss, N. S., Iyer, R., Sheth, K., Sharpe, O., Rao, N. L., Becart, S., Carman, J. A., James, E. A., Buckner, J. H., Deane, K. D., Holers, V. M., Goodman, S. M., Donlin, L. T., Davis, M. M., Robinson, W. H. 2023; 14 (1): 319

    Abstract

    The immune mechanisms that mediate synovitis and joint destruction in rheumatoid arthritis (RA) remain poorly defined. Although increased levels of CD8+ T cells have been described in RA, their function in pathogenesis remains unclear. Here we perform single cell transcriptome and T cell receptor (TCR) sequencing of CD8+ T cells derived from anti-citrullinated protein antibodies (ACPA)+ RA blood. We identify GZMB+CD8+ subpopulations containing large clonal lineage expansions that express cytotoxic and tissue homing transcriptional programs, while a GZMK+CD8+ memory subpopulation comprises smaller clonal expansions that express effector T cell transcriptional programs. We demonstrate RA citrullinated autoantigens presented by MHC class I activate RA blood-derived GZMB+CD8+ T cells to expand, express cytotoxic mediators, and mediate killing of target cells. We also demonstrate that these clonally expanded GZMB+CD8+ cells are present in RA synovium. These findings suggest that cytotoxic CD8+ T cells targeting citrullinated antigens contribute to synovitis and joint tissue destruction in ACPA+ RA.

    View details for DOI 10.1038/s41467-022-35264-8

    View details for PubMedID 36658110

    View details for PubMedCentralID PMC9852471

  • Intranasal administration of nucleus-deliverable GATA3-TMD alleviates the symptoms of allergic asthma BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS Lee, S., Kim, J., Seong, Y., Moon, J., Kim, Y., Shin, B., Shin, J., Park, J., Park, C., Lee, S. 2023; 640: 32-39

    Abstract

    Although the T helper 2 (Th2) subset is a critical player in the humoral immune response to extracellular parasites and suppression of Th1-mediated inflammation, Th2 cells have been implicated in allergic inflammatory diseases such as asthma, allergic rhinitis, and atopic dermatitis. GATA binding protein 3 (GATA3) is a primary transcription factor that mediates Th2 differentiation and secretion of Th2 cytokines, including IL-4, IL-5, and IL-13. Here, a nucleus-deliverable form of GATA3-transcription modulation domain (TMD) (ndG3-TMD) was generated using Hph-1 human protein transduction domain (PTD) to modulate the transcriptional function of endogenous GATA3 without genetic manipulation. ndG3-TMD was shown to be efficiently delivered into the cell nucleus quickly without affecting cell viability or intracellular signaling events for T cell activation. ndG3-TMD exhibited a specific inhibitory function for the endogenous GATA3-mediated transcription, such as Th2 cell differentiation and Th2-type cytokine production. Intranasal administration of ndG3-TMD significantly alleviated airway hyperresponsiveness, infiltration of immune cells, and serum IgE level in an OVA-induced mouse model of asthma. Also, Th2 cytokine secretion by the splenocytes isolated from the ndG3-TMD-treated mice substantially decreased. Our results suggest that ndG3-TMD can be a new therapeutic reagent to suppress Th2-mediated allergic diseases through intranasal delivery.

    View details for DOI 10.1016/j.bbrc.2022.11.095

    View details for Web of Science ID 000927575800005

    View details for PubMedID 36502629

  • Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA) Gomez, A., Brewer, C., Moon, J., Acharya, S., Lanz, T. V., Wang, Q., Min-Oo, G., Niedziela-Majka, A., Robinson, W. WILEY. 2022: 69-70
  • High dose of bile acid enables the cellular entry and replication of hepatitis C virus in vitro (Apr, 10.1007/s13273-022-00232-2, 2022) MOLECULAR & CELLULAR TOXICOLOGY Lee, H., Shin, B., Moon, J., Antonio, J., Fadriquela, A., Ho, C., Shin, J., Yoon, J., Lee, S., Kim, S. 2022; 18 (4): 649
  • High dose of bile acid enables the cellular entry and replication of hepatitis C virus in vitro MOLECULAR & CELLULAR TOXICOLOGY Lee, H., Shin, B., Moon, J., Antonio, J., Fadriquela, A., Ho, C., Shin, J., Yoon, J., Lee, S., Kim, S. 2022; 18 (4): 589-598
  • Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM. Nature Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J. S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G. S., Bartley, C. M., Schubert, R. D., Hawes, I. A., Vazquez, S. E., Iyer, M., Zuchero, J. B., Teegen, B., Dunn, J. E., Lock, C. B., Kipp, L. B., Cotham, V. C., Ueberheide, B. M., Aftab, B. T., Anderson, M. S., DeRisi, J. L., Wilson, M. R., Bashford-Rogers, R. J., Platten, M., Garcia, K. C., Steinman, L., Robinson, W. H. 2022

    Abstract

    Multiple sclerosis (MS) is a heterogenous autoimmune disease in which autoreactive lymphocytes attack the myelin sheath of the central nervous system (CNS). B lymphocytes in the cerebrospinal fluid (CSF) of MS patients contribute to inflammation and secrete oligoclonal immunoglobulins1,2. Epstein-Barr virus (EBV) infection has been linked to MS epidemiologically, but its pathological role remains unclear3. Here we demonstrate high-affinity molecular mimicry between the EBV transcription factor EBNA1 and the CNS protein GlialCAM, and provide structural and in-vivo functional evidence for its relevance. A cross-reactive CSF-derived antibody was initially identified by single-cell sequencing of the paired-chain B cell repertoire of MS blood and CSF, followed by protein microarray-based testing of recombinantly expressed CSF-derived antibodies against MS-associated viruses. Sequence analysis, affinity measurements, and the crystal structure of the EBNA1-peptide epitope in complex with the autoreactive Fab fragment allowed for tracking the development of the naïve EBNA1-restricted antibody to a mature EBNA1/GlialCAM cross-reactive antibody. Molecular mimicry is facilitated by a post-translational modification of GlialCAM. EBNA1 immunization exacerbates the mouse model of MS and anti-EBNA1/GlialCAM antibodies are prevalent in MS patients. Our results provide a mechanistic link for the association between MS and EBV, and could guide the development of novel MS therapies.

    View details for DOI 10.1038/s41586-022-04432-7

    View details for PubMedID 35073561

  • Intranuclear Delivery of HIF-1α-TMD Alleviates EAE <i>via</i> Functional Conversion of TH17 Cells FRONTIERS IN IMMUNOLOGY Shin, J., Kim, I., Moon, J., Ho, C., Choi, M., Ghosh, S., Lee, S. 2021; 12: 741938

    Abstract

    T helper 17 (TH17) cells are involved in several autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). In addition to retinoic acid receptor-related orphan nuclear receptor gamma t (ROR-γt), hypoxia-inducible factor-1α (HIF-1α) is essential for the differentiation and inflammatory function of TH17 cells. To investigate the roles of HIF-1α in the functional regulation of TH17 cells under the normal physiological condition without genetic modification, the nucleus-transducible form of transcription modulation domain (TMD) of HIF-1α (ntHIF-1α-TMD) was generated by conjugating HIF-1α-TMD to Hph-1 protein transduction domain (PTD). ntHIF-1α-TMD was effectively delivered into the nucleus of T cells without cellular cytotoxicity. ntHIF-1α-TMD significantly blocked the differentiation of naïve T cells into TH17 cells in a dose-dependent manner via IL-17A and ROR-γt expression inhibition. However, T-cell activation events such as induction of CD69, CD25, and IL-2 and the differentiation potential of naïve T cells into TH1, TH2, or Treg cells were not affected by ntHIF-1α-TMD. Interestingly, TH17 cells differentiated from naïve T cells in the presence of ntHIF-1α-TMD showed a substantial level of suppressive activity toward the activated T cells, and the increase of Foxp3 and IL-10 expression was detected in these TH17 cells. When mRNA expression pattern was compared between TH17 cells and ntHIF-1α-TMD-treated TH17 cells, the expression of the genes involved in the differentiation and functions of TH17 cells was downregulated, and that of the genes necessary for immune-suppressive functions of Treg cells was upregulated. When the mice with experimental autoimmune encephalomyelitis (EAE) were treated with ntHIF-1α-TMD with anti-IL-17A mAb as a positive control, the therapeutic efficacy of ntHIF-1α-TMD in vivo was comparable with that of anti-IL-17A mAb, and ntHIF-1α-TMD-mediated therapeutic effect was contributed by the functional conversion of TH17 cells into immune-suppressive T cells. The results in this study demonstrate that ntHIF-1α-TMD can be a new therapeutic reagent for the treatment of various autoimmune diseases in which TH17 cells are dominant and pathogenic T cells.

    View details for DOI 10.3389/fimmu.2021.741938

    View details for Web of Science ID 001050886600001

    View details for PubMedID 34745114

    View details for PubMedCentralID PMC8566938

  • Critical role of bile acid (BA) in the cellular entry and permissiveness of Hepatitis B virus in vitro MOLECULAR & CELLULAR TOXICOLOGY Lee, H., Shin, B., Moon, J., Fadriquela, A., Nuwormegbe, S., Ho, C., Shin, J., Yoon, J., Lee, S., Kim, S. 2020; 16 (3): 221-231
  • Decremental effect of non-host humoral milieu interfacing viral envelope on the RNA level and surface antigenicity of hepatitis C virus (HCV) in vitro MOLECULAR & CELLULAR TOXICOLOGY Lee, H., Shin, B., Moon, J., Ho, C., Shin, J., Kim, S., Lee, S. 2019; 15 (3): 239-244
  • Regulatory effect of humoral milieu on the viral DNA and surface antigen expression of hepatitis B virus (HBV) in vitro MOLECULAR & CELLULAR TOXICOLOGY Lee, H., Shin, B., Moon, J., Ho, C., Shin, J., Yoon, J., Yang, J., Kim, S., Lee, S. 2019; 15 (2): 123-128
  • Therapeutic Effects of HIF-1 on Bone Formation around Implants in Diabetic Mice Using Cell-Penetrating DNA-Binding Protein MOLECULES Oh, S., Shin, J., Kim, I., Kim, J., Moon, J., Lee, S., Lee, J. 2019; 24 (4)

    Abstract

    Patients with uncontrolled diabetes are susceptible to implant failure due to impaired bone metabolism. Hypoxia-inducible factor 1α (HIF-1α), a transcription factor that is up-regulated in response to reduced oxygen during bone repair, is known to mediate angiogenesis and osteogenesis. However, its function is inhibited under hyperglycemic conditions in diabetic patients. This study thus evaluates the effects of exogenous HIF-1α on bone formation around implants by applying HIF-1α to diabetic mice and normal mice via a protein transduction domain (PTD)-mediated DNA delivery system. Implants were placed in the both femurs of diabetic and normal mice. HIF-1α and placebo gels were injected to implant sites of the right and left femurs, respectively. We found that bone-to-implant contact (BIC) and bone volume (BV) were significantly greater in the HIF-1α treated group than placebo in diabetic mice (p < 0.05). Bioinformatic analysis showed that diabetic mice had 216 differentially expressed genes (DEGs) and 21 target genes. Among the target genes, NOS2, GPNMB, CCL2, CCL5, CXCL16, and TRIM63 were found to be associated with bone formation. Based on these results, we conclude that local administration of HIF-1α via PTD may boost bone formation around the implant and induce gene expression more favorable to bone formation in diabetic mice.

    View details for DOI 10.3390/molecules24040760

    View details for Web of Science ID 000460805900106

    View details for PubMedID 30791543

    View details for PubMedCentralID PMC6412638

  • Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor CLINICAL RHEUMATOLOGY Moon, J., Lee, D., Park, Y., Lee, S. 2018; 37 (10): 2771-2779

    Abstract

    We investigated the rate of rheumatoid factor (RF) false positivity at diagnosis and its influence on clinical and prognostic features and rheumatoid arthritis (RA) development during the follow-up in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients without RA or other medical conditions triggering RF false positivity. We reviewed the medical records of 128 AAV patients. We divided patients with AAV and each variant into two groups according to RF positivity and compared variables between the two groups. Odds ratio and cumulative relapse-free survival rate were obtained by multivariate logistic regression analysis and the Kaplan-Meier survival analysis, respectively. The mean age at diagnosis was 53.6 years and 41 patients were male. Of 128 AAV patients, 69 patients (53.9%) were classified as microscopic polyangiitis (MPA), 29 (22.7%) as granulomatosis with polyangiitis (GPA) and 30 (23.4%) as eosinophilic GPA (EGPA). The rate of RF false positivity was 39.1% in AAV patients. On univariate analysis, general, cutaneous and mucous and ocular manifestations and myeloperoxidase (MPO)-ANCA (or perinuclear (P)-ANCA) positivity were associated with RF false positivity in patients with AAV. On multivariate analysis, cutaneous manifestation was the only independent predictor of RF false positivity in EGPA patients. RF false positivity had no influence on cumulative relapse-free survival rate of AAV or RA development during the follow-up. RF false positivity rate was 39.1% in AAV patients and it was associated with cutaneous manifestation in EGPA patients at diagnosis, but not relapses of AAV or RA development during the follow-up.

    View details for DOI 10.1007/s10067-017-3902-4

    View details for Web of Science ID 000444749500021

    View details for PubMedID 29119480

  • Immuno-suppressive function of nucleus-transducible BAF57-PH in T cell activation via degradation of endogenous BAF57 INTERNATIONAL JOURNAL OF HEMATOLOGY Moon, J., Lee, H., Ho, C., Shin, J., Ghosh, S., Kim, J., Lee, S. 2018; 108 (4): 375-383

    Abstract

    The BAF57 subunit, an indispensable member of the BAF complex, is functionally implicated in apoptosis, cell cycle, and T cell development through chromosomal remodeling. However, the precise roles of BAF57 in the T cell receptor (TcR)-mediated signaling pathway have not been elucidated. In this study, a nucleus-transducible form of BAF57, absent the proline-rich and HMG domains (ntBAF57-ΔPH), was generated to interfere with the interaction between BAF57 and its binding protein, BAF155. ntBAF57-ΔPH was effectively delivered into mouse CD4+ T cells in a dose- and time-dependent manner, without cellular toxicity. Inhibition of T cell activation by ntBAF57-ΔPH was mediated by its disruption of the interaction between BAF155 and BAF57, leading to the degradation of endogenous BAF57 and BAF155. This phenomenon led to alterations in gene expression similar to those associated with Ciclosporin A treatment. In vivo administration of ntBAF57-ΔPH enhanced survival rate of sepsis-induced mice and reduced the LPS-induced secretion of pro-inflammatory cytokines and the expression of endogenous BAF57. These results reveal a novel function of BAF57 as an essential regulator of T cell activation. ntBAF57-ΔPH represents a novel immune-suppressive drug candidate with potential uses in the treatment of autoimmunity and graft rejection.

    View details for DOI 10.1007/s12185-018-2491-6

    View details for Web of Science ID 000445096400006

    View details for PubMedID 29978433

  • C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with ANCA-Associated Vasculitis YONSEI MEDICAL JOURNAL Moon, J., Ahn, S., Park, Y., Lee, S., Lee, S. 2018; 59 (7): 865-871

    Abstract

    We investigated whether C-reactive protein (CRP) to serum albumin ratio (CAR) could be an independent predictor of all-cause mortality in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).We retrospectively reviewed the medical records of 170 patients with AAV. We collected clinical and laboratory data. We also examined AAV-related and traditional risk factors of all-cause mortality. To assess the hazard ratios of variables, we performed univariable and multivariable Cox hazard model analyses.The mean age was 55.0 years and 53 patients (31.2%) were male among 170 patients with AAV (88 microscopic polyangiitis, 43 granulomatosis with polyangiitis, and 39 eosinophilic granulomatosis with polyangiitis). ANCA was detected in 129 patients (75.9%). The initial mean CRP and serum albumin were 41.1 (mg/L) and 3.6 (g/dL), and the mean CAR at diagnosis was 14.8. The most common risk factor of mortality was hypertension (42.4%), followed by chronic kidney disease ≥stage 3 (25.9%). Fourteen patients (8.2%) died during the mean follow-up of 56.7 months. In both multivariable Cox hazard model analyses, CAR at diagnosis was identified as an independent predictor of all-cause of mortality comparable to diabetes mellitus (DM). Moreover, patients with CAR ≥10.35 and having DM exhibited a higher frequency of all-cause mortality than those without.CAR at diagnosis can be an independent predictor of all-cause mortality, comparable to DM, the conventional risk factor of mortality.

    View details for DOI 10.3349/ymj.2018.59.7.865

    View details for Web of Science ID 000441158200008

    View details for PubMedID 30091320

    View details for PubMedCentralID PMC6082976

  • Intranuclear delivery of the transcription modulation domain of Tbet-improved lupus nephritis in (NZB/NZW) F1 lupus-prone mice KIDNEY INTERNATIONAL Moon, J., Mun, C., Kim, J., Cho, J., Park, S., Park, T., Shin, J., Ho, C., Park, Y., Ghosh, S., Bothwell, A. L. M., Lee, S., Lee, S. 2018; 93 (5): 1118-1130

    Abstract

    Excessive expression of Tbet and IFNγ is evidence of systemic lupus erythematosus (SLE) in lupus patients. In this study, the nucleus-transducible form of Transcription Modulation Domain (TMD) of Tbet (ntTbet-TMD), which is a fusion protein between Protein Transduction Domain Hph-1 (Hph-1-PTD) and the TMD of Tbet comprising DNA binding domain and isotype-specific domain, was generated to inhibit Tbet-mediated transcription in the interactomic manner. ntTbet-TMD was effectively delivered into the nucleus of the cells and specifically inhibited Tbet-mediated transcription without influencing the differentiation of other T cell subsets and signaling events for T cell activation. The severity of nephritis was significantly reduced by ntTbet-TMD as effectively as methylprednisolone in lupus-prone mice. The number of Th1, Th2 or Th17 cells and the secretion of their cytokines substantially decreased in the spleen and kidney of lupus-prone mice by ntTbet-TMD treatment. In contrast to methylprednisolone, the marked increase of Treg cells and the secretion of their immunosuppressive cytokine were detected in the spleen of (NZB/NZW) F1 mice treated with ntTbet-TMD. Thus, ntTbet-TMD can improve nephritis in lupus-prone mice by modulating the overall proinflammatory microenvironment and rebalancing T cell subsets, leading to new immune therapeutics for Th1-mediated autoimmune diseases.

    View details for DOI 10.1016/j.kint.2017.11.017

    View details for Web of Science ID 000430681400015

    View details for PubMedID 29409726

  • <i>HIF1A</i> overexpression using cell-penetrating DNA-binding protein induces angiogenesis in vitro and in vivo MOLECULAR AND CELLULAR BIOCHEMISTRY Jeon, M., Shin, Y., Jung, J., Jung, U., Lee, J., Moon, J., Kim, I., Shin, J., Lee, S., Song, J. 2018; 437 (1-2): 99-107

    Abstract

    Hypoxia-inducible factor-1 alpha (HIF1A) is an important transcription factor for angiogenesis. Recent studies have used the protein transduction domain (PTD) to deliver genes, but the PTD has not been used to induce the expression of HIF1A. This study aimed at using a novel PTD (Hph-1-GAL4; ARVRRRGPRR) to overexpress the HIF1A and identify the effects on angiogenesis in vitro and in vivo. Overexpression of HIF1A was induced using Hph-1-GAL4 in human umbilical vein/vascular endothelium cells (HUVEC). The expression levels of genes were analyzed by the quantitative real-time polymerase chain reaction (qPCR) after 2 and 4 days, respectively. An in vitro tube formation was performed using Diff-Quik staining. HIF1A and Hph-1-GAL4 were injected subcutaneously into the ventral area of each 5-week-old mouse. All of the plugs were retrieved after 1 week, and the gene expression levels were evaluated by qPCR. Each Matrigel plug was evaluated using the hemoglobin assay and hematoxylin and eosin (HE) staining. The expression levels of HIF1A and HIF1A target genes were significantly higher in HIF1A-transfected HUVEC than in control HUVEC in vitro. In the in vivo Matrigel plug assay, the amount of hemoglobin was significantly higher in the HIF1A-treatment group than in the PBS-treatment group. Blood vessels were identified in the HIF1A-treatment group. The expression levels of HIF1A, vascular endothelial growth factor (Vegf), and Cd31 were significantly higher in the HIF1A-treatment group than in the PBS-treatment group. These findings suggest that using Hph-1-G4D to overexpress HIF1A might be useful for transferring genes and regenerating tissues.

    View details for DOI 10.1007/s11010-017-3098-6

    View details for Web of Science ID 000419379100008

    View details for PubMedID 28660411